Integrisani biomarkeri za remodeliranje upale-imunog-matriksa za dijagnozu i stratifikaciju stadijuma primarnog karcinoma grkljana
Inflammation–Immune Biomarkers in Laryngeal Cancer
Sažetak
Background: aryngeal squamous cell carcinoma (LSCC) is characterized by complex interactions among systemic inflammation, immune dysregulation, and extracellular matrix remodeling. Circulating biomarkers reflecting these biological processes may provide valuable tools for disease detection and stratification; however, their integrated diagnostic value in primary LSCC remains insufficiently defined.
Methods: We conducted a case–control study including 50 treatment-naïve LSCC patients and 50 healthy controls. Levels of YKL-40, soluble urokinase plasminogen activator receptor (suPAR) and matrix metalloproteinase-9 (MMP-9) in serum were quantified using ELISA. Systemic inflammation was evaluated via the CRP/albumin ratio and neutrophil-to-lymphocyte ratio (NLR). Receiver operating characteristic (ROC) curves assessed the diagnostic performance of individual and combined biomarkers, and associations with tumor stage were analyzed according to the AJCC 8th edition.
Results: LSCC patients exhibited significantly higher serum levels of YKL-40 (112.6 ± 28.4 vs. 54.3 ± 15.7 ng/mL), suPAR (4.32 ± 0.98 vs. 2.15 ± 0.61 ng/mL), and MMP-9 (386.5 ± 82.3 vs. 201.7 ± 56.9 ng/mL), along with increased CRP/Alb ratio (0.186 ± 0.072 vs. 0.062 ± 0.028) and NLR (3.21 ± 1.04 vs. 1.68 ± 0.52) (all P < 0.001), compared to healthy controls. ROC analysis demonstrated good diagnostic accuracy for individual biomarkers (AUC values 0.74 to 0.85), while MMP-9 showed the highest individual performance (AUC = 0.85). An integrated multivariate model combining YKL-40, suPAR, MMP-9, CRP/Alb ratio, and NLR achieved superior diagnostic accuracy (AUC = 0.92), with 88.0% sensitivity and 90.0% specificity. Furthermore, advanced-stage patients had higher levels of YKL-40, suPAR, and MMP-9 than early-stage patients (P < 0.001), indicating a close association between biomarker expression and tumor progression.
Conclusions: An integrated panel of inflammation–immune–matrix remodeling biomarkers is markedly dysregulated in primary LSCC and demonstrates strong diagnostic and stage-stratification value. The combined biomarker model outperforms individual markers, supporting its utility in clinical evaluation and risk assessment.
Reference
2. Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Medical Sciences (Basel, Switzerland) 2023; 11(2): 42.
3. Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Tar 2023; 8(1): 200.
4. Zhou H, Xin-Yan Y, Yu W, Liang X, Du X, Liu Z, et al. Lactic acid in macrophage polarization: The significant role in inflammation and cancer. Int Rev Immunol 2022; 41(1): 4-18.
5. Videmark AN, Christensen IJ, Feltoft CL, Villadsen M, Borg FH, Jørgensen BM, et al. Combined plasma C-reactive protein, interleukin 6 and YKL-40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer. Cancer Med-Us 2023; 12(6): 6675-88.
6. Belvederi F, Leggeri S, Urbani A, Baroni S. suPAR as a biomarker of support in different clinical settings. Clinica Chimica Acta; International Journal of Clinical Chemistry 2025; 573: 120303.
7. Srivastava A, Gupta J, Singhal S, Tulli H, Mishra N, Atale N, et al. Matrix Metalloproteinase-9: A Key Diagnostic Biomarker in Cancer Progression. Curr Drug Targets 2025: 10-2174.
8. Koca T, Cetmi DA, Aksoy RA, Korcum AF. The Predictive Role of Inflammatory Biomarkers in Patients With Larynx Cancer Undergoing Definitive Radiotherapy. Technol Cancer Res T 2024; 23: 15330338241280433.
9. Yung AE, Que MS, Lo S, Aggarwal S, Hong AM, Tin MM, et al. Validation of the American Joint Committee on Cancer Staging in Squamous Cell Carcinoma of the Vermilion Lip. Ann Surg Oncol 2021; 28(6): 3092-9.
10. Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun 2021; 12(1): 7338.
11. Cai J, Yi M, Tan Y, Li X, Li G, Zeng Z, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Canc Res 2021; 40(1): 190.
12. Li G, Zhang D, Li M, Yuan F, Hou X, He D, et al. Association between the neutrophil-to-lymphocyte ratio and cancer in adults from NHANES 2005-2018: a cross-sectional study. Sci Rep-Uk 2024; 14(1): 23678.
13. Gao Q, Quan M, Zhang L, Ran Y, Zhong J, Wang B. Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer. Cancer Control : Journal of the Moffitt Cancer Center 2024; 31: 10732748241309048.
14. Zhang T, Li Y, Zhai E, Zhao R, Qian Y, Huang Z, et al. Intratumoral Fusobacterium nucleatum Recruits Tumor-Associated Neutrophils to Promote Gastric Cancer Progression and Immune Evasion. Cancer Res 2025; 85(10): 1819-41.
15. Rashid ZA, Bardaweel SK. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment. International Journal of Molecular Sciences 2023; 24(15): 12133.
16. Chen TK, Estrella MM, Katz R, Sarnak MJ, Grams ME, Cushman M, et al. Plasma Biomarkers of Kidney Health and Mortality in Diabetes and Chronic Kidney Disease in the REGARDS Study. Clinical Journal of the American Society of Nephrology: CJASN 2024; 19(12): 1585-93.
17. Kjaergaard AD, Vaag AA, Jensen VH, Olsen MH, Højlund K, Vestergaard P, et al. YKL-40 and risk of incident cancer in early type 2 diabetes: a Danish cohort study. Brit J Cancer 2025; 132(11): 1019-26.
18. Li D, Hemati H, Park Y, Taftaf R, Zhang Y, Liu J, et al. ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer. Cancers 2023; 15(10): 2734.
19. Aronen A, Aittoniemi J, Huttunen R, Nikkola A, Rinta-Kiikka I, Nikkola J, et al. Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer. Scand J Gastroentero 2021; 56(1): 81-5.
20. Hamada M, Varkoly KS, Riyadh O, Beladi R, Munuswamy-Ramanujam G, Rawls A, et al. Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator. Biomedicines 2024; 12(6): 1167.
Sva prava zadržana (c) 2026 Kaisheng Lin, Jiongcong Yuan, Ying Wang
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.